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Abstract 12 
Epizootic hemorrhagic disease virus (EHDV) is a distinct species within the genus 13 
Orbivirus, within the family Reoviridae. The epizootic hemorrhagic disease virus 14 
genome comprises ten segments of linear, double stranded (ds) RNA, which are 15 
packaged within each virus particle. The EHDV virion has a three layered capsid-16 
structure, generated by four major viral proteins: VP2 and VP5 (outer capsid layer); 17 
VP7 (intermediate, core-surface layer) and VP3 (innermost, sub-core layer). Although 18 
EHDV infects cattle sporadically, several outbreaks have recently occurred in this 19 
species in five Mediterranean countries, indicating a potential threat to the European 20 
cattle industry. EHDV is transmitted by biting midges of the genus Culicoides, which 21 
can travel long distances through wind-born movements (particularly over water), 22 
increasing the potential for viral spread in new areas /countries. Expression systems to 23 
generate self-assembled virus like particles (VLPs) by simultaneous expression of the 24 
major capsid-proteins, have been established for several viruses (including bluetongue 25 
virus). This study has developed expression systems for production of EHDV VLPs, for 26 
use as non-infectious antigens in both vaccinology and serology studies, avoiding the 27 
risk of genetic reassortment between vaccine and field strains and facilitating large scale 28 
antigen production. Genes encoding the four major-capsid proteins of a field strain of 29 
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EHDV-6, were isolated and cloned into transfer vectors, to generate two recombinant 30 
baculoviruses. The expression of these viral genes was assessed in insect cells by 31 
monitoring the presence of specific viral mRNAs and by western blotting. Electron 32 
microscopy studies confirmed the formation and purification of assembled VLPs.  33 
 34 
Keywords: Epizootic hemorrhagic disease virus; baculovirus expression system; insect 35 
cells; virus like particles. 36 
 37 
1. Introduction  38 
 39 
Epizootic hemorrhagic disease virus (EHDV) is a distinct virus species within the genus 40 
Orbivirus, belonging to the family Reoviridae. Epizootic hemorrhagic disease virus 41 
particles are non-enveloped, approximately 62-80 nm in diameter with a similar 42 
structure to bluetongue virus (BTV), which is classified as the prototype of this genus 43 
(Mertens et al.; 2005; Savini et al., 2011; Attoui et al.; 2012). The EHDV genome is 44 
made of ten segments of linear dsRNA which encode seven structural proteins (VP1-45 
VP7) and probably, as recently discovered for BTV four non-structural proteins (NS1-46 
NS4) (Belhouchet et al., 2011; Mecham and Dean, 1988; Ratinier et al., 2011; Stewart 47 
et al., 2015). The ten segments of the EHDV genome are enclosed, along with three 48 
minor enzymatic proteins (VP1, VP4 and VP6) within the three-layered, icosahedral 49 
virus capsid composed of the four ‘major’ structural proteins. The sub-core shell is 50 
formed by 120 copies of VP3, the core-surface layer comprises 780 copies of VP7, 51 
while the outer-capsid contains 180 copies of VP2 and 360 copies of VP5. VP3 is part 52 
of the viral ‘scaffolding’ and contributes to the correct size and structure of the virus. 53 
VP7 is the major core protein and is widely used as an orbivirus serogroup/species-54 
specific antigen in serological assays (Luo and Sabara, 2005; Mecham and Wilson, 55 
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2004). VP2, which is the outermost ‘exposed’ EHDV protein, is responsible for 56 
receptor-binding on target cells and determines virus-serotype through the specificity of 57 
its interactions with neutralizing antibodies. According to some reports, VP5, which is a 58 
membrane permeabilization protein, may also contribute to the specificity of the 59 
neutralizing antibody response, and like VP5 of BTV it has been shown to enhance the 60 
immune response induced by VP2 alone. On the basis of antigenic and genetic analyses 61 
of the two outer capsid proteins (VP2 and VP5), the EHDV serogroup has been 62 
proposed to comprise seven serotypes, although there is not yet a widely accepted 63 
consensus on their exact number (Anthony et al., 2010, 2009a, 2009b, 2009c; Maan et 64 
al., 2010; Viarouge et al., 2015).  65 
White-tailed deer (Odocoileus virginianus) is the species most severely affected by 66 
EHDV, while mule deer and pronghorn antelope are less severely affected. Although 67 
black-tailed deer, red deer, wapiti, fallow deer, roe deer, elk, moose, and bighorn sheep 68 
do not appear to be severely affected, they may seroconvert, indicating that they can 69 
become infected (MacLachlan and Osburn, 2004; Noon et al., 2002a, 2002b). Recently 70 
EHDV has also been isolated in yaks (Van Campen et al., 2013). Goats do not seem to 71 
be susceptible to EHDV infection and sheep can be infected experimentally but rarely 72 
develop clinical signs, and a recent study has excluded a role in transmission to more 73 
susceptible species (Kedmi et al., 2011a).  74 
Cattle were first found to be susceptible to infection by an EHDV-2 strain, named as 75 
Ibaraki virus, in Japan during 1959. This strain has subsequently been associated with 76 
periodic outbreaks in cattle in East Asia (Hirashima et al., 2015; Kitano Y., 2004). In 77 
recent years EHDV-6 and 7 have been involved in several outbreaks in cattle: EHDV-6 78 
in Turkey, Algeria, Morocco, Reunion Island and French Guiana (Albayrak et al., 2010; 79 
Cêtre-Sossah et al., 2014; Temizel et al., 2009; Viarouge et al., 2014); EHDV-7 in Israel 80 
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in 2006 (Eschbaumer et al., 2012; Wilson et al., 2015; Yadin et al., 2008). During 2007 81 
and most recently, EHDV-2 caused morbidity in dairy cattle in Ohio and Kentucky 82 
(Garrett et al., 2015) (ProMed Archive Number: 20150923.3666422). EHDV-6 was 83 
identified for the first time in the USA, during 2006 and by 2008 was widespread, 84 
although the new isolates were all reassortants containing genome segments derived 85 
from the parental strains of EHDV-2 and 6 (Allison et al., 2010, 2012; Anbalagan et al., 86 
2014a). EHDV has recently also been isolated in Brazil (Favero et al., 2013). The 87 
extended host range of EHDV-6 and 7 in cattle has caused major concerns for 88 
international authorities and in 2008 the disease was included in the Office International 89 
Epizootics (OIE) list of multispecies / transboundary diseases (OIE, 2012).  90 
 Analogous to BTV and several other members of the genus Orbivirus, EHDV is 91 
transmitted by midges of the genus Culicoides (Brown et al., 1992; Paweska et al., 92 
2005) which can travel long distances by wind-borne movements particularly over 93 
water, making it possible for infected vectors to move from North Africa and Middle 94 
East to Southern Europe (Kedmi et al., 2010a; Lorusso et al., 2014). However, there has 95 
been little interest so far in developing vaccines to control the disease or EHDV 96 
circulation. To date an autogenous vaccine that can be used only in captive wild deer, 97 
has been developed in USA. In Japan, both live modified and inactivated vaccines have 98 
been developed to control Ibaraki disease in cattle (Ohashi et al., 1999). 99 
Virus like particles (VLPs) are considered as a safer and effective alternative to live 100 
attenuated vaccines, and VLPs have been generated and tested as non infective 101 
immunogens both for human and animal diseases (including bluetongue), triggering the 102 
same immunological responses as the whole virus. VLP have the advantage of being 103 
immunogens with the same structural characteristics as the native virus particle but are 104 
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free of the viral genetic material and cannot therefore pose a risk of transmission (Lua et 105 
al., 2014; Roy and Noad, 2008; Stewart et al., 2012; Zhao et al., 2013).  106 
VLPs of BTV were generated several years ago using baculovirus expression systems 107 
and more recently by expression in plants (French et al., 1990; Hewat et al., 1994; Le 108 
Blois et al., 1991; Pérez de Diego et al., 2011; Roy, 1990; Roy et al., 1994; Stewart et 109 
al., 2010; Thuenemann et al., 2013). Although their use as immunogens, as well as tools 110 
to understand BTV replication has been well established, so far nothing similar has been 111 
done for EHDV.  112 
We report the generation of VLPs derived from a strain of EHDV-6 (MOR2006/05), 113 
isolated from disease outbreaks in the Morocco during 2006. These VLPs could be used 114 
as antigens to generate a safe and effective vaccine. The omission of non-structural 115 
proteins from these VLPs, would allow development of serological assays that could be 116 
used to distinguish infected from vaccinated animals (DIVA). This is not currently 117 
possible with the live modified vaccines or conventional inactivated vaccines that have 118 
been developed for the orbiviruses. The same VLPs, or a combination of individual 119 
virus-structural proteins produced by recombinant technology, might be also used as 120 
purified antigens for serological diagnosis.  121 
2. Material and Methods 122 
2.1 Virus propagation 123 
The virus used in this study EHDV-6 (MOR2006/05) was obtained from the Orbivirus 124 
Reference Collection (ORC) at The Pirbright Institute (Pirbright, UK) 125 
(http://www.reoviridae.org/dsRNAvirusproteins /ReoID/EHDV-Nos.htm). Virus was 126 
propagated in BHK-21 cells (clone 13 obtained from European Collection of Animal 127 
cell Cultures (ECACC – 84100501), supplied with Dulbecco’s minimum essential 128 
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medium (DMEM) supplemented with antibiotics (100 units/ml penicillin and 100 µg/ml 129 
streptomycin) and 2 mM glutamine. Infected cell cultures were incubated until they 130 
showed widespread (100%) cytopathic effects (CPE). Viruses were harvested, aliquoted 131 
and used for the dsRNA extraction, or stored in the ORC at -80°C. 132 
2.2 Preparation of viral dsRNA:  133 
Intact genomic dsRNA of EHDV-6 was extracted from infected cell cultures using a 134 
guanidinium isothiocyanate procedure as described by Attoui et al., (2000). Briefly, the 135 
infected cell pellet was lysed in 1 ml of commercially available TRIZOL
®
 reagent 136 
(Thermo Fisher Scientific, MA, USA), then 0.2 volume of chloroform was added, 137 
mixed by vortexing and the mixture was incubated on ice for 10 minutes (min). The 138 
supernatant containing total RNA was separated from cellular debris and DNA by 139 
centrifuging at 10,000 g at 4°C for 10 min. Single stranded RNA (ssRNA) was 140 
precipitated by adding 2 M LiCl and then incubating at 4°C overnight, followed by 141 
centrifugation at 10,000 g for 5 min. The supernatant containing dsRNA was mixed 142 
with an equal volume of isopropanol containing 750 mM ammonium acetate and 143 
incubated at -20°C for a minimum of 2 hours (hrs). The dsRNA was pelleted by 144 
centrifugation at 10,000 g for 10 min, washed with 70% ethanol, air dried and 145 
suspended in nuclease free water. The RNA was either used immediately or stored at -146 
80°C.  147 
2.3 Reverse transcription, PCR amplification and cloning of EHDV cDNAs 148 
Genome segments encoding VP2, VP3, VP5 and VP7 of EHDV-6 (MOR2006/05) were 149 
reverse-transcribed using a ‘full-length amplification of cDNA’ (FLAC) technique 150 
described by Maan et al (2007). Briefly, a 35 base self-priming oligonucleotide ‘anchor-151 
primer’, with a phosphorylated 5` terminus was ligated to the 3` ends of the viral 152 
dsRNAs using the T4 RNA ligase, followed by reverse transcription with the RT system 153 
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(Promega, MA, USA). The resulting cDNAs were amplified using a high fidelity KOD 154 
polymerase (Merck Millipore, Darmstadt, Germania,) and 5-15-1-NOT-S primers (5`-155 
GCAGTTTAGAATCCTCAGAGGTC-3`), then analyzed by agarose gel electrophoresis 156 
and purified using an illustra GFX™ PCR DNA and Gel Band Purification Kit (GE 157 
Healthcare, Little Chalfont, UK). The amplified cDNAs of Seg-6 and Seg-7, encoding 158 
for VP5 and VP7 respectively, were cloned into the Strataclone blunt-end PCR cloning 159 
vector ‘pSC-B-amp/kan’ supplied in the StrataClone Blunt PCR cloning kit (Agilent 160 
Technologies, CA,USA) and the recombinant plasmid vectors were transformed into 161 
Solopack® competent cells (Agilent Technologies, CA,USA). Amplicons of Seg-2 and 162 
Seg-3 (encoding for VP2 and VP3 respectively) were cloned into the ‘pCR®-Blunt’ 163 
vector supplied with the Zero Blunt® PCR Cloning Kit. Clones containing the desired 164 
inserts were identified by colony touch PCR using M13 universal primers and GoTaq® 165 
Hot start polymerase (Promega, MA, USA). Plasmid DNA was isolated using the 166 
QIAprep® Spin Miniprep kit (Qiagen, Heidelberg, Germany), quantified using a 167 
NanoDrop® ND-1000 Spectrophotometer (Labtech, Uckfield, UK) and stored at -20ºC 168 
until further use. Sequencing was done using an automated ABI 3730 DNA sequencer 169 
(Thermo Fisher Scientific, MA, USA).  170 
2.4 Cloning of EHDV capsid proteins ORFs into baculovirus transfer vectors 171 
The cDNA sequences coding for the viral proteins were cloned into pAcUW51® 172 
transfer vector (BD Bioscience, CA, USA), which enables the simultaneous expression 173 
of two viral proteins by the baculovirus promoters, polyhedrin (Ph) and p10, having 174 
opposite orientations. By this approach two different transfer vectors have been 175 
generated: one carrying the VP2/VP5 genes (pU2/5) and another carrying the VP3/VP7 176 
open reading frames (ORFs) (pU3/7). Sequences for the VP3 and VP5 ORFs were 177 
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excised from the original vectors by EcoRI digestion and ligated into EcoRI digested 178 
pAcUW51®, so that they could both be inserted downstream of the p10 promoter.  179 
The VP2 and VP7 ORFs were amplified by PCR using cloning plasmids containing 180 
either the VP2 or VP7 sequences as templates, which were generated as described in 181 
section 2.3. Both cDNAs were inserted downstream the Ph promoter. Primers were 182 
designed to introduce BamHI sites at both ends of the amplicons. The primers used for 183 
the VP2 ORF (with BamHI sites underlines) are: VP2 BamHI Fwd2: 184 
CGCGGATCCAGGTTAAATTGTTCCAGGATGGATAGCGTT; VP2 BamHI Rev2: 185 
CGCGGATCCGTAAGTGTGTTGTTCCAGGTAATCTCTGTC. The following primers 186 
were used for the VP7 ORF: BamHI Fwd2: 187 
CGCGGATCCGTTAAAATTTGGTGAAGATGGAC; VP7 BamHI Rev2: 188 
CGCGGATCCGTAAGTTTGAATTTGGGAAAACGTAC. 189 
After restriction digestion with BamHI, amplicons were ligated into the BamHI site of 190 
the transfer vector pAcUW51®. Recombinant plasmids were identified by restriction 191 
digestion and verified by sequence analysis.  192 
2.5 Generation of recombinant baculoviruses 193 
Recombinant baculoviruses were generated by homologous recombination between 194 
transfer vectors encoding the EHDV-6 capsid proteins genes and the linearised 195 
baculovirus DNA, as previously described (French et al., 1990; Kitts et al., 1990; 196 
Possee, 1997).  This part of the work has been carried out using two different insect cell 197 
lines both belonging to Spodoptera frugiperda (Sf): transfection, viral amplification and 198 
plaque assay procedures were performed on Sf21 cells; virus infection for the 199 
production of VLPs was done using Sf9 cells.  200 
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In particular, the pU2/5 and pU3/7 transfer vectors and linearised Baculogold® AcNPV 201 
DNA (Autographa californica nuclear polyhedrosis virus) (BD Bioscience, CA, USA) 202 
were cotransfected in Sf21 (Spodoptera frugiperda) cells using the cellfectin® 203 
transfection reagent, following the manufacturer’s instructions (Thermo Fisher 204 
Scientific, MA, USA). As a control a baculovirus expressing the CAT gene 205 
(Chloramphenicol acetyltransferase) was generated by cotransfecting the transfer vector 206 
pENTR-CAT DNA along with the linearised baculodirect N-terminal DNA following 207 
the manufactures procedures (Thermo Fisher Scientific, MA, USA).  Cells were grown 208 
as monolayer in TC-100 medium (Thermo Fisher Scientific, MA, USA) at 28°C. At day 209 
5 post infection (p.i.) cytopathic effect was detectable, supernatant was harvested and a 210 
plaque assay was performed. Recombinant plaques were selected by their lacZ-negative 211 
phenotype, resulting in the formation of white plaques when stained with 1% x-gal (5-212 
bromo-4-chloro-3-indolyl-β-D-galactopyranoside) (Sigma-Aldrich,MO, USA) . Isolated 213 
plaques were harvested and amplified to generate viral stocks, namely BacpU2/5 and 214 
BacpU3/7, that were stored at 4°C in the dark.  215 
2.6 Detection of viral mRNA in infected cells 216 
To check whether the recombinant baculoviruses were expressing EHDV genes, 217 
infected Sf9 cells were tested for the presence of EHDV mRNA. Sf9 cells were infected 218 
separately with each of the recombinant viruses using a multiplicity of infection (MOI) 219 
of 5. The cells were harvested after 48 hrs and total RNA extraction and DNase I 220 
digestion were performed using the RNeasy® mini kit, following the manufacturer’s 221 
protocol (QIAGEN, Heidelberg, Germany). Total RNA was eluted in 40 µl of RNase-222 
free water. RNAs obtained from each infection (BacpU2/5 and BacpU3/7) were 223 
transcribed into cDNAs. Reactions were carried out using Superscript III® Reverse 224 
Transcriptase (Thermo Fisher Scientific, MA, USA) following the manufacturer’s 225 
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instructions. The cDNAs were used as templates in PCR reactions using primers 226 
specific either for VP2,VP5, VP3 and VP7 (Tab 1). Amplicons were run on a 1% 227 
agarose gel. Markers used are the following : M1: MassRuler™ High Range DNA 228 
ladder, M2: MassRuler™ Low Range DNA ladder (Thermo Fisher Scientific, MA, 229 
USA). 230 
2.7 SDS/PAGE and western blotting of recombinant EHDV-6 protein expression  231 
Sf9 cells were grown as suspension culture in Sf900 II serum free medium (Thermo 232 
Fisher Scientific, MA, USA) and plated on a six well plate at1x10
6 
per well. Infection 233 
with recombinant baculoviruses along with the Bac-CAT control was carried  with   234 
MOIs of 5.  Cells were harvested at 72 hrs post infection and lysed. Samples were run 235 
on a precast 4-12% Bolt® Bis-Tris polyacrylamide gel (Thermo Fisher Scientific, MA, 236 
USA) . The gels were either stained with Coomassie brilliant blue or were subjected to 237 
western blotting using both a rabbit polyclonal antibody against EHDV-1 and a mouse 238 
polyclonal anti-EHDV-1 VP7 kindly donated by Prof. Polly Roy (London School of 239 
Hygiene and Tropical Medicine, UK). Peroxidase conjugated goat anti rabbit and a goat 240 
anti mouse secondary antibodies (Thermo Fisher Scientific, MA, USA) were used. 241 
EHDV-6 infected cell lysate was run next to the samples (courtesy of The Pirbright 242 
Institute, UK) as a positive control. As additional positive control purified CLPs kindly 243 
donated by Prof. Matsuo were also run (Matsuo et al., 2015). Sharp Mass V plus  244 
(Euroclone, Milan, Italy) was used as marker. 245 
2.8 Generation and purification of VLPs 246 
EHDV VLPS were purified as described for BTV (French et al., 1990; Stewart et al., 247 
2010). Infections were carried out on Sf9 cells grown to a density of 1x10
6
/ml, in a total 248 
volume of 100 ml (total cell number 1x10
8
). Each virus was used with a MOI of 5 and 249 
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cells were harvested at 68-72 hrs post infection, when cell mortality had reached about 250 
70-80%. Samples were centrifuged at 2,000 g and supernatants removed. Cells were 251 
resuspended in lysis buffer (10 mM Tris-HCl pH 8,5; 50 mM NaCl; 10 mM EDTA) and 252 
homogenised in ice by a dounce homogenizer in presence of a protease inhibitor 253 
cocktail. Lysates were centrifuged once more to remove all cellular debris and the 254 
supernatant loaded on top of a 40-66% sucrose gradient (in 0.02 M Tris-HCl pH 8,5). 255 
Samples were centrifuged in a 80K Beckman ultracentrifuge (Beckman Coulter, CA, 256 
USA) on a SW41Ti rotor at 28,000 rpm, for 3 hrs at 4°C. After centrifugation a band 257 
was visible on the expected position at the interface between 40-66% gradient. The band 258 
was collected from the top, diluted into 0.02 M Tris-HCl pH 8.5, loaded on top of a 2 ml 259 
cushion consisting of 20% sucrose (in 0.02 M Tris-HCl pH 8.5) and run as before but 260 
for only 30 min. The pellet was finally resuspended in 100 µl of 0.02 M Tris-HCl pH 261 
8.5.  262 
2.9 Electron microscopy of VLPs 263 
A two step protocol was used for the specimen preparation: VLP samples in 20 mM 264 
Tris-HCl pH 8.5, were adsorbed for 30 min onto carbon-coated 300 mesh grids 265 
(Electron Microscope Science, Hatfield, PA, USA) washed three times with sterile 266 
deionised/distilled water and stained for 30 min with 3% uranyl acetate solution in 267 
ethanol, followed by draining of grids. All grids were analyzed using a Zeiss Libra 120 268 
Plus transmission electron microscope, operating at 120 kV and equipped with an in-269 
column omega filter and 16-bit CCD camera 2k x 2k bottom mounted (Zeiss, 270 
Oberkichen, Germany). 271 
 272 
 273 
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3. Results 274 
3.1 Generation of recombinant baculoviruses 275 
The regions of the EHDV genome encoding VP2, VP5, VP3 and VP7 were amplified by 276 
PCR from a EHDV-6 field isolate (MOR2006/05) and individually cloned into two 277 
different vectors to generate four recombinant plasmids. Amplicons of Seg-6 and Seg-7, 278 
coding for VP5 and VP7 were cloned into pSC-B-amp/kan’, while amplicons of Seg-2 279 
and Seg-3, coding for VP2 and VP3 were cloned into the ‘pCR®-Blunt’ vector. The viral 280 
genes were then inserted into the pAcUW51® transfer vector, which allows 281 
simultaneous expression of two genes, thereby generating pU2/5 and pU3/7. The correct 282 
insertion of the viral genes into pAcUW51® was confirmed by sequence analysis. 283 
Recombinant baculoviruses, BacpU2/5 and BacpU3/7, were generated by homologous 284 
recombination, after co-transfecting each recombinant transfer vector along with the 285 
linearised baculovirus DNA in Sf21 cells. The presence of cytopathic effect on the 286 
transfected cells and the plaque assay in the presence of x-gal indicated that almost 287 
100% of the plaques were made by recombinant viruses. Single plaques were harvested 288 
and the virus was amplified by passage in Sf21 cell cultures. 289 
3.2 Expression of EHDV proteins in recombinant-baculovirus infected cells 290 
The ability of the recombinant baculoviruses to express the EHDV proteins was 291 
monitored by checking for the presence of viral mRNAs in infected Sf9 cells. RT-PCR 292 
analysis using primers specific for each viral gene readily detected mRNAs of the 293 
expected sizes for the EHDV-6 VP3, VP5 and VP7 genes in recombinant baculoviruses 294 
infected cells. While an amplicon of 1126 bp was generated for VP3, for VP5 and VP7 295 
the entire viral gene was amplified producing a single band of 1641 and 1162 bp 296 
respectively (Fig 1A). The VP2 mRNAs was more difficult to detect on the first PCR 297 
using the cDNA as template and the couple of primers VP2A (Table 1). On the other 298 
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hand, when this product was used as template for a semi-nested PCR using primers 299 
defined as VP2B (Table 1) we were able to  detect an amplicon of 751 bp as expected 300 
(Fig 1B).  As a negative control, in order to show specificity of the primers for the viral 301 
genes,  uninfected Sf9 cells were also lysate, total RNA extracted and used as template 302 
for the generation of cDNA.  However, the synthesis of all four viral proteins was 303 
subsequently confirmed by the presence of protein bands of the expected sizes on SDS-304 
PAGE stained with Coomassie-blue. Proteins bands were visible with molecular weights 305 
of 100 and 38 KDa (for VP3 and VP7 respectively), and with 110 and 60 KDa for VP2 306 
and VP5 (Fig 2). In order to harvest infected cells when protein expression was highest, 307 
Sf9 cells were infected at different MOIs and analysed at different time points. 308 
Optimum conditions were identified as an MOI of 5 for each virus stock, with cell 309 
harvested at 3 days p.i. Data obtained confirmed that the four inner and outer capsid 310 
proteins of EHDV-6 were all expressed in the insect cells. 311 
3.3 Purification and isolation of EHDV VLPs from insect cells 312 
Assembly of complete VLPs requires simultaneous expression of the viral inner and 313 
outer capsid proteins. Therefore it was necessary to co-infect insect cells with both 314 
recombinant baculoviruses. In order to provide high cell density, infection was 315 
performed on suspension cultures. Each virus was used at a MOI of 5 and the cells 316 
harvested between 68-72 hrs post infection. The presence of all four viral capsid 317 
proteins was confirmed by western blotting of the purified particles. Although the 318 
antibodies used were raised against EHDV-1 proteins, they were able to identify EHDV-319 
6 proteins as shown in figure 3. EM analysis of purified VLPs showed particles of the 320 
expected size and morphology for EHDV VLPs. We also observed smaller particles 321 
resembling core like particles (CLPs) generated by the assembly of only VP3 and VP7 322 
to form the viral inner core structure (Fig 4). The observed morphology of the VLPs 323 
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was similar to those generated for BTV (French et al., 1990; Hewat et al., 1994; Stewart 324 
et al., 2010; Thuenemann et al., 2013). The data obtained indicated that the viral 325 
proteins expressed by the recombinant baculoviruses where able to assemble so to 326 
generate properly sized and shaped VLPs. This could also indirectly indicate that the 327 
folding and the molar ratio of each protein of each recombinant protein was maintained.  328 
4. Discussion 329 
In recent years, diseases transmitted by arthropod vectors such as mosquitoes and 330 
Culicoides have become an increasingly important concern for animal and human 331 
health. The presence and dissemination of Arthropod-borne viruses in countries where 332 
they were not formerly present can be caused either through the movement of animals 333 
by trade, shifting of the geographical range of vectors driven by global warming, or 334 
possibly by the introduction/movement of even small numbers of infected adult vectors 335 
(Carpenter et al., 2011). The reported co-circulation of BTV and EHDV in several 336 
countries during 2011 and 2012, indicates that both viruses can be present 337 
simultaneously within the same host and vector populations (Sailleau et al., 2012; Toye 338 
et al., 2013; Viarouge et al., 2014). Although EHDV has long been regarded as a 339 
causing only infrequent outbreaks in cattle, clinical disease similar to bluetongue has 340 
been reported on several occasions, since 2005, in five Mediterranean countries as well 341 
as in the USA (Breard et al., 2013). Recent sequence analyses of EHDV isolates from 342 
cattle with clinical disease in Indiana (USA) indicate high identity levels to the EHDV-2 343 
reference strain isolated from a white tailed deer, suggesting that similar viruses can 344 
circulate in both species, posing a threat to both wildlife and cattle (Anbalagan and 345 
Hause, 2014b). Furthermore, when the EHDV-7 strain isolated from infected cattle in 346 
Israel was used to experimentally infect white tailed deer, they developed clinical signs 347 
similar to EHD caused by north American EHDV strains (Ruder et al., 2012). 348 
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Serological and epidemiological investigations of Israeli cattle, after the 2006 EHD 349 
outbreaks, found high seroprevalence for EHDV and BTV which clustered together 350 
(Kedmi et al., 2011b). 351 
 The economic losses due to EHDV infection of dairy cattle during the outbreak in 352 
Israel in 2006 were estimated as US$2.5 million due to reduced milk and meat 353 
production (Kedmi et al., 2010b), therefore a possible outbreak of EHDV in susceptible 354 
and naïve European cattle would be economically important. 355 
In the event of a major new outbreak, the availability of diagnostic reagents (proteins 356 
and antibodies) assays and vaccines would represent key components of any control 357 
programs. Unlike modified live vaccines, the use of EHDV VLPs as a immunogen, like 358 
inactivated vaccines, would avoid the risk of vaccine strain transmission and genetic 359 
reassortment between vaccine strains and wild type viruses circulating in the field. 360 
However, unlike the inactivated vaccines, a VLP based vaccine would be compatible 361 
with the use of serological DIVA assays for continued surveillance adopting  a viral non 362 
structural protein based ELISA since those are not present in VLPs. 363 
We report the generation of EHDV VLPs from a field strain of EHDV-6 (MOR2006/05) 364 
isolated in Morocco in 2006, that caused outbreaks in cattle in several countries and was 365 
reported to reassort with other EHDV strains. The genome segments coding for 366 
structural viral proteins VP2,VP3,VP5 and VP7 were successfully isolated, transcribed 367 
into cDNAs and cloned into baculovirus transfer vectors, to generate two recombinant 368 
baculoviruses, each expressing two viral proteins. The correct expression of EHDV 369 
genes was initially assessed by monitoring the synthesis of each viral mRNA in infected 370 
Sf9 cells and was then confirmed by western blot analysis. The correct assembly of 371 
these proteins into VLPs was finally verified by EM showing a correct VLP 372 
morphology and size.  373 
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We have demonstrated that expression of all four viral structural proteins allows them to 374 
self-assemble into non-infectious and morphologically correct particle antigens that 375 
could be used safely without risk of infection, for diagnostic test development, or 376 
vaccination strategies. This approach could be also used to explore the replication 377 
strategies of the virus in vivo and in vitro, by inserting mutation into the structural viral 378 
proteins VP2, VP3, VP5 or VP7 to elucidate their roles in virus infection. 379 
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Figures Legend 634 
 635 
Fig 1 Analysis of viral mRNAs.  636 
Analysis of RT-PCR samples on a 1% agarose gel; (A): PCR products generated from 637 
VP3 (1116 bp),VP5 (1640 bp)and VP7 (1162) ORF cDNAs using specific primers; (B): 638 
PCR product for the VP2 ORF (750 bp) using higher concentration of cDNA template.  639 
 640 
Fig 2 Protein expression studies.  641 
Samples were run on a precast 4-12% Bolt® Bis-Tris polyacrylamide gel (Thermo 642 
Fisher Scientific, MA, USA)  and the proteins stained with Coomassie-blue. As  a 643 
positive control purified CLPswere run next to the samples.  644 
Fig 3 Western blotting on purified VLPs.  645 
Purified EHDV VLP particles were run on a 4-12% Bolt® Bis-Tris precast 646 
polyacrylamide gel (Thermo Fisher Scientific, MA, USA) and, after blotting, proteins 647 
were detected by polyclonal antibodies as described in materials and methods. As  648 
positive controls, EHDV-6 infected cell lysate and purified CLPs  were run next to the 649 
samples.  650 
 651 
 Fig.4 EM studies on purified VLPs.  652 
Purified VLP particles were stained and visualized as described in material and 653 
methods. Size bars are of 200 nm on upper panel and 50 nm on lower panels. Black 654 
arrow indicates CLP and white arrow purified VLPs.  655 
 656 
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Gene Primers Size (bp) 
 
 
VP2 
 
 
 
VP2A 
129F 
1547R 
 
VP2B 
796F         
1547R      
 
5’ GCTTATAGTGGTGAAAAGGAAGG 3’ 
5’CGATGCCGCCCACATCCGAG 3’ 
 
 
5’AGTGAAGCGTATCGAGAGGTTGCT 3’ 
5’CGATGCCGCCCACATCCGAG 3’ 
 
1318 
 
 
 
751 
VP3 
826F        
1952R     
5’GTGCTTACCGACAGGAGAATACGTCT 3’ 
5’AGGCTCTGGCGATACTTCCATAACA 3’ 
1126 
VP5 
BamHIF  
BamHIR   
5’CGCGGATCCGTTAAAAAGATCCAGTGCCGTTGCAAAATGG 3’ 
5’CGCGGATCCGTAAGTTGAAGATCCGAATACCATCCGC 3’ 
1641 
VP7 
BamHIF   
BamHIR   
5’CGCGGATCCGTTAAAATTTGGTGAAGATGGAC 3’ 
5’CGCGGATCCGTAAGTTTGAATTTGGGAAAACGTAC 3’ 
1162 
 657 
Tab. 1 List of primers used for the PCRs performed on viral cDNAs  658 
  659 
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